Sagimet says partner trial shows denifanstat sustains acne efficacy through 52 weeks

• Sagimet flagged positive 52-week acne data for oral denifanstat from Ascletis’ Phase 3 open-label extension in China.
• Results will be presented at the 2026 Fall Clinical Dermatology Conference in Las Vegas, running Oct. 8-11.
• The study showed sustained clinical improvement across key acne endpoints over a year, with tolerability broadly consistent with earlier findings.
• The update supports fatty acid synthase inhibition as a potential new oral approach for acne, strengthening the program’s commercial rationale.
• AURORA, the U.S. Phase 3 trial, has activated sites and started screening patients as Sagimet advances global development outside China.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610090700PRIMZONEFULLFEED9842625) on October 09, 2026, and is solely responsible for the information contained therein.